Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci ...

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

Researchers assessed whether combination mosunetuzumab and polatuzumab vedotin would reduce the risk of disease progression or death in patients with LBCL.

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...

One of the oldest challenges in oncology is creating a drug that kills cancer cells while sparing healthy ones. Peptides are ...

Patritumab deruxtecan shows meaningful clinical activity in heavily pretreated patients with metastatic breast cancer and ...

Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin- converting enzyme 2 (ACE2) is widely ...